Cargando…

Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy

It has been estimated that 80% of the pre-mRNA undergoes alternative splicing, which exponentially increases the flow of biological information in cellular processes and can be an attractive therapeutic target. It is a crucial mechanism to increase genetic diversity. Disturbed alternative splicing i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lejman, Jan, Zieliński, Grzegorz, Gawda, Piotr, Lejman, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468182/ https://www.ncbi.nlm.nih.gov/pubmed/34573328 http://dx.doi.org/10.3390/genes12091346

Ejemplares similares

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives
por: Lejman, Jan, et al.
Publicado: (2023)

Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes
por: Singh, Natalia N., et al.
Publicado: (2007)

The Importance of Selected Dysregulated microRNAs in Diagnosis and Prognosis of Childhood B-Cell Precursor Acute Lymphoblastic Leukemia
por: Ziętara, Karolina Joanna, et al.
Publicado: (2023)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Emerging therapies and challenges in spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2017)

Revisiting the role of mitochondria in spinal muscular atrophy
por: James, Rachel, et al.
Publicado: (2021)

Alternative Splicing Events Are a Late Feature of Pathology in a Mouse Model of Spinal Muscular Atrophy
por: Bäumer, Dirk, et al.
Publicado: (2009)

miRNA in spinal muscular atrophy pathogenesis and therapy
por: Magri, Francesca, et al.
Publicado: (2017)

Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature
por: Ręka, Gabriela, et al.
Publicado: (2023)

Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders
por: Jablonka, Sibylle, et al.
Publicado: (2022)

New therapies for spinal muscular atrophy: where we stand and what is next
por: Antonaci, Laura, et al.
Publicado: (2023)

Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy
por: Van Alstyne, Meaghan, et al.
Publicado: (2018)

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia
por: Obszański, Piotr, et al.
Publicado: (2022)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
por: López-Cortés, Andrés, et al.
Publicado: (2022)

New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
por: Messina, Sonia, et al.
Publicado: (2020)

Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies
por: Angilletta, Ilaria, et al.
Publicado: (2023)

The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies
por: Leśniak, Maria, et al.
Publicado: (2023)

Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms
por: Lejman, Monika, et al.
Publicado: (2021)

Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
por: Tsai, Li-Kai
Publicado: (2012)

The role of ubiquitination in spinal and bulbar muscular atrophy
por: Sengupta, Medha, et al.
Publicado: (2022)

Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy
por: Ahmad, Saif, et al.
Publicado: (2016)

Advances and limitations for the treatment of spinal muscular atrophy
por: Day, John W., et al.
Publicado: (2022)

Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy
por: Babić, Marija, et al.
Publicado: (2023)

CAR T-Cell Therapy in Children with Solid Tumors
por: Kulczycka, Marika, et al.
Publicado: (2023)

CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
por: Ostojska, Magdalena, et al.
Publicado: (2023)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients
por: Derebas, Justyna, et al.
Publicado: (2022)

SAM68 is a physiological regulator of SMN2 splicing in spinal muscular atrophy
por: Pagliarini, Vittoria, et al.
Publicado: (2015)

Editorial: Diagnosis and therapy pediatric hematological malignancies: recent progress
por: Zawitkowska, Joanna, et al.
Publicado: (2023)

Insight into the Molecular Basis Underlying Chromothripsis
por: Ostapińska, Katarzyna, et al.
Publicado: (2022)

Straight to the Point—The Novel Strategies to Cure Pediatric AML
por: Lejman, Monika, et al.
Publicado: (2022)

Gene therapy for spinal muscular atrophy: the Qatari experience
por: Ali, Hossamaldein Gaber, et al.
Publicado: (2021)

Antisense-based therapy for the treatment of spinal muscular atrophy
por: Rigo, Frank, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_srfupsmal1fcdbuvrc14n6od8e